Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) on Monday, plunged -6.91% from the previous trading day, before settling in for the closing price of $2.75. Within the past 52 weeks, ZNTL’s price has moved between $2.66 and $18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 45.10%. With a float of $56.61 million, this company’s outstanding shares have now reached $71.15 million.
In an organization with 168 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.68%, operating margin of -490.5%, and the pretax margin is -419.76%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zentalis Pharmaceuticals Inc is 20.57%, while institutional ownership is 83.17%. The most recent insider transaction that took place on Jan 02 ’25, was worth 13,762. In this transaction Chief Scientific Officer of this company sold 4,411 shares at a rate of $3.12, taking the stock ownership to the 191,317 shares. Before that another transaction happened on Oct 31 ’24, when Company’s Former Chief Medical Officer proposed sale 9,888 for $2.86, making the entire transaction worth $28,294.
Zentalis Pharmaceuticals Inc (ZNTL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.10% per share during the next fiscal year.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Zentalis Pharmaceuticals Inc (ZNTL) is currently performing well based on its current performance indicators. A quick ratio of 7.29 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -2.93 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Let’s dig in a bit further. During the last 5-days, its volume was 1.79 million. That was better than the volume of 1.65 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 6.12%. Additionally, its Average True Range was 0.27.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 3.36%, which indicates a significant decrease from 11.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.78% in the past 14 days, which was lower than the 87.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.31, while its 200-day Moving Average is $5.99. However, in the short run, Zentalis Pharmaceuticals Inc’s stock first resistance to watch stands at $2.71. Second resistance stands at $2.86. The third major resistance level sits at $2.99. If the price goes on to break the first support level at $2.43, it is likely to go to the next support level at $2.31. Assuming the price breaks the second support level, the third support level stands at $2.16.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
Market capitalization of the company is 182.44 million based on 71,265K outstanding shares. Right now, sales total 0 K and income totals -292,190 K. The company made 0 K in profit during its latest quarter, and -88,280 K in sales during its previous quarter.
